DDInter927 DDInter1623
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
Rotavirus vaccine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Carmustine
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Rotavirus vaccine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Rotavirus vaccine may lead to a major life threatening interaction when taken with Carmustine
Rotavirus vaccine may lead to a major life threatening interaction when taken with Sarilumab